Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI

This study is testing an adaptive radiotherapy approach — where the radiation plan is adjusted throughout treatment based on MRI scans showing how the tumor responds — for people with stage III non-small cell lung cancer (NSCLC) that cannot be surgically removed. **You may be eligible if...** - You are 18–75 years old with confirmed unresectable stage III non-small cell lung cancer - You have not received prior radiation or surgery for this cancer - You can undergo MRI scans - Your lung function, blood counts, and organ function meet required levels - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have had prior chest radiation or lung surgery - You cannot tolerate MRI scans (e.g., metal implants, severe claustrophobia) - You have poor lung function (FEV1 below 800 mL) - You have other serious uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.